Lilly has been approved for the obesity-control diabetes drub ‘Trulicity’ in the domestic market
It is observed that Lilly Korea will launch the new diabetes treatment with the GLP-1 analogue type.
The drug type is the obesity-control diabetes drug, which has been highly interested by the current market.
The type, having dulaglutide as the main substance, is a diabetes product of the GLP-1...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
